Skip to content

A preliminary study of transcranial magnetic stimulation (TMS) for hemodialysis patients with cognitive dysfunction based on magnetic resonance imaging

A preliminary study of transcranial magnetic stimulation (TMS) for hemodialysis patients with cognitive dysfunction based on magnetic resonance imaging

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200061349
Enrollment
Unknown
Registered
2022-06-21
Start date
2022-06-09
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End-stage renal disease

Interventions

Really stimulate group:transcranial magnetic stimulation(TMS)
Sham stimulation group:Sham TMS

Sponsors

The First Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years old, right-handed; 2. Signed informed Consent (ICF); 3. received regular dialysis treatment more than 3 months; 4. Cognitive impairment (10=MOCA score =25).

Exclusion criteria

Exclusion criteria: 1. Malignancies affecting survival time (except for tumors determined to be cured or in remission for more than 5 years, radical excised basal cell or squamous cell carcinoma of the skin or carcinoma in situ anywhere); 2. The patient's life expectancy is less than 6 months (as judged by the doctor); 3. Pregnant or lactating women; Women of childbearing age did not agree to use effective contraception during the trial; 4. Severe visual, hearing and communication disorders, unable to complete cognitive function assessment and intervention measures; 5. Patients after kidney transplantation; 6. Serious psychological disorders and mental disorders; 7. Patients who have already participated in other intervention programs; 8. Known cerebral hemorrhage, non-lacunar cerebral infarction, metabolic encephalopathy (such as hepatic encephalopathy, uremic encephalopathy, hypoxic encephalopathy, etc.), traumatic brain injury, epilepsy, encephalitis, hydrocephalus, brain tumor, multiple sclerosis, and other central nervous system diseases; 9. MRI contraindications: including cochlear implants, metal dentures, pacemakers, and other metal implants and known claustrophobia; 10. Serious primary diseases such as digestive system diseases, hematopoietic system diseases, congestive heart failure, malignant hypertension, epilepsy, etc.; History of idiopathic epilepsy in first-degree relatives; 11. Use of medications that may affect cognitive function, including sedatives, antianxiety medications, and cholinergic drugs.

Design outcomes

Primary

MeasureTime frame
cognitive function score;3D T1 structural Image;Brain network connection;metabonomics;

Secondary

MeasureTime frame
Beck anxiety inventory (BAI);Beck depression inventory (BDI);Adverse events;

Countries

China

Contacts

Public ContactJiang Hongli

The First Affiliated Hospital of Xi'an Jiaotong University

j92106@sina.com+86 13700280897

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026